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ABSTRACT
Background: Few studies have compared ovarian cancer
rates between different ethnic groups in the same
country. The aim of this study was to describe ethnic
patterns in the incidence and mortality of ovarian cancer
in New Zealand, and to investigate ethnic and socio-
economic differences in the grade and stage of ovarian
cancer.
Methods: Data on all women registered with ovarian
cancer on the New Zealand Cancer Registry (1993-2004)
were analysed. Population data were taken from the 1996
and 2001 census. Logistic regression was used to
estimate associations between ethnicity, deprivation and
tumour characteristics.
Results: Age-standardised incidence rates were highest
in Pacific women, intermediate in Ma¯ori women, and
lowest in non-Ma¯ori, non-Pacific women. Age-standar-
dised mortality rates showed the same pattern. Ovarian
cancer subtypes differed by ethnic group. There was no
significant association between socioeconomic depriva-
tion and tumour grade or stage. Age-adjusted models
showed that Ma¯ori women were more likely to have well-
differentiated tumours and less likely to present at a later
stage compared to non-Ma¯ori, non-Pacific women. These
patterns were partly explained by socioeconomic depri-
vation, and were not apparent for Pacific women.
Conclusions: Pacific and Ma¯ori women experience
higher incidence of ovarian cancer and mortality, compared
to non-Ma¯ori, non-Pacific women. Ma¯ori women seemed to
have better prognostic factors (local stage and well-
differentiated tumours) than non-Ma¯ori, non-Pacific women.
More work is needed to improve current cancer prevention
strategies, particularly in Pacific women.
The incidence of ovarian cancer in New Zealand is
similar to comparable countries, being slightly
higher than Australia, Canada and the USA, but
lower than the UK.1 In 2003, ovarian cancer
accounted for 2.9% of all female cancer registra-
tions in New Zealand, and it ranked eighth highest
in frequency of all female cancers.2 International
comparisons of mortality are similar, with New
Zealand having rates between those in North
America and the UK.1 The proportion of all female
deaths due to ovarian cancer was 4.4% in New
Zealand. It is ranked the fourth highest cause of
female cancer deaths, and has the highest age-
standardised death rate (5.2 deaths per 100 000
females) of all reproductive cancers.2
Few studies have compared ovarian cancer rates
between different ethnic populations in the same
country, or between women of the same ethnic
origin living in different countries. One recent
investigation found little variation in incidence
rates of ovarian cancer between urban women in
India and South Asian women in Singapore, the
UK and the USA.3 In the USA, the incidence rates
of ovarian cancer in African–American women are
lower than in white women (rate ratio 0.7).4
Until recently, comparisons of incidence of and
mortality from ovarian cancer have not been made
between ethnic groups in New Zealand. Routinely
published incidence and mortality data have only
just begun to include ethnic-specific estimates for
Pacific people but these rates are very imprecise,
being based on data for only 1 year.2 It has been
suggested that ovarian cancer is somewhat more
common in New Zealand Polynesians than European
New Zealanders,5 and this is backed up by one
analysis showing that Ma¯ori and Pacific women in
New Zealand have one of the highest age-standar-
dised incidence rates of ovarian cancer worldwide
(13.8 and 17.6 per 100 000 respectively).6 7
The aims of the current paper are twofold. First,
to describe the incidence and mortality of ovarian
cancer between Ma¯ori, Pacific and non-Ma¯ori non-
Pacific women residing in New Zealand for the period
1993–2004; and second, to describe ethnic and socio-
economic differences in the grade and stage of ovarian
cancer, and to see whether these are explained by
socioeconomic position or ethnicity respectively.
METHODS
Data were obtained from the New Zealand Cancer
Registry (NZCR) of all women with a primary
diagnosis of ovarian cancer (ICD-10-AM, Second
Edition, code C56) from July 1993 to December
2004. The information extracted from the NZCR
data included tumour grade and stage, histology
subtypes of ovarian cancer, and basic demographic
information, including age and ethnicity.
The NZCR characterises ovarian tumour grade
in four distinct categories: well-differentiated, mod-
erately differentiated, poorly differentiated, and
undetermined or not known. Since 1999, the record-
ing of tumour stage, or the extent of the disease was
standardised using the Surveillance, Epidemiology
and End Results (SEER) Guide to Summary Staging.8
Prior to this, the New Zealand Health Information
Service (NZHIS) used the numeric extent of disease
codes, assigned by cancer registrars, which were
applied to registrations up to and including 1998.9
Thus, combining the SEER guide and the numeric
code, tumour stage was categorised into four cate-
gories: local, regional, distant and not known.
Age at diagnosis was grouped in two ways for
different analyses. For descriptive analyses, age at
diagnosis was divided into 15 5-year age-bands
from 14–19 years to 85 years and older. For logistic
regression analyses, age was included as a contin-
uous variable.
Research report
814 J Epidemiol Community Health 2009;63:814–819. doi:10.1136/jech.2008.081497
In New Zealand, ethnic differences are an important
consideration in examining and planning appropriate health
services, particularly where there are policies aimed at reducing
disparities in health between Ma¯ori, Pacific peoples and others
(non-Ma¯ori non-Pacific).10 The NZCR utilises a prioritisation
system for classification of ethnicity, where the highest priority
is given to Ma¯ori, followed by Pacific ethnic groups. Thus, for
the analyses in this study, ethnicity was grouped into three
categories: Ma¯ori, Pacific, and non-Ma¯ori non-Pacific women,
using the standard prioritisation system.11
To measure socioeconomic position, domicile codes provided
by the NZHIS to the New Zealand Deprivation Index 2001
(NZDep2001) were converted, as a standardised measure of
socioeconomic deprivation. Based on the 2001 New Zealand
Census, the index combines nine census variables. The index
provides a deprivation score for each small area unit (‘‘mesh-
block’’) in New Zealand. These meshblocks are defined by
Statistics New Zealand as geographical units, which contain a
median of 90 people. Each meshblock is categorised between 1
(least deprived) and 10 (most deprived).12 For our analyses,
deciles were grouped into quintiles: 1–2 (least deprived); 3–4;
5–6; 7–8; 9–10 (most deprived).
Analyses
The analyses were performed with the SASTM (version 9.01)
statistical package. Chi-squared tests were used to examine
ethnic differences for clinical and demographic variables.
Logistic regression was used to estimate odds ratios (OR) and
95% confidence intervals (95% CI) to investigate associations
between ethnicity, socioeconomic deprivation and clinical
variables (tumour stage and grade). In each instance, two
logistic models were run for each dependent variable (grade and
stage of tumour); the first model involved calculation of the age-
adjusted OR, whereas the second model also included either
ethnicity or deprivation, accordingly.
Ovarian cancer incidence (or mortality) was defined as the
number of new registered ovarian cases (or ovarian cancer
deaths) (aged 14+ years) during 1993–2004 per 100 000 person-
years. For the denominator, census population estimates were
obtained from 1993–2004 for each ethnic group: Pacific, Ma¯ori,
and non-Ma¯ori non-Pacific peoples. Age standardisation of
incidence and mortality rates was conducted using Segi’s 1960
World Population weights.13
Missing data (n = 195) were excluded from the analyses,
where domicile codes could not be matched to the NZDep2001
index. Fifteen cases were also omitted registered under age 14, or
over age 95 years.
RESULTS
Based on the age at diagnosis, there were 3110 women who
were registered on the NZCR from 1993 to 2004 as having
ovarian cancer as their primary cancer diagnosis. Non-Ma¯ori
non-Pacific women comprised 88% of the cases, whereas Ma¯ori
accounted for 8% and Pacific women 4%. The average age at
first diagnosis was 60.4 years (49.8 years for Ma¯ori women
(p,0.001), 52.1 years for Pacific women (p,0.001), compared
to 61.7 years for non-Ma¯ori non-Pacific women). Table 1 shows
the distributions of clinical and demographic characteristics, by
ethnicity. For stage of tumour, Ma¯ori women were more likely to
be diagnosed with localised disease than non-Ma¯ori non-Pacific
women. Across all ethnic groups, there was a large proportion of
women (80%) with tumour grade coded as ‘‘undetermined’’,
‘‘unknown’’, ‘‘not supplied’’ or ‘‘not applicable’’, thus they do not
have a histological grade assigned. Among those who did have
histology performed, Ma¯ori women were more likely to have well-
differentiated tumours compared to non-Ma¯ori non-Pacific
women. Table 1a shows the distribution of ovarian cancer
subtypes, by ethnicity. Serous tumours were the most commonly
recorded histological subtypes of ovarian cancer for Ma¯ori and
non-Ma¯ori non-Pacific women (36.7% and 40.1% respectively).
The most common ovarian cancer subtype among Pacific women
was epithelial tumours (51.4%).
Incidence
Table 2 shows the age-specific incidence rates of ovarian cancer,
by ethnicity, in New Zealand. Pacific women have the highest
age-standardised incidence rates of ovarian cancer (11.2 per
100 000 Pacific women, 95% CI 9.5 to 14.0), whereas Ma¯ori
women were intermediate (10.1 per 100 000 Ma¯ori women,
95% CI 8.8 to 11.5), and the lowest rates were seen in non-
Ma¯ori non-Pacific women (9.4 per 100 000, 95% CI 8.9 to 9.7).
Although the 95% confidence intervals for Ma¯ori and Pacific
women were wide, there was only a small degree of overlap
comparing Pacific to non-Ma¯ori non-Pacific women.
Mortality
In table 3, Pacific women had the highest age-standardised
mortality rate of 6.3 deaths per 100 000 Pacific women (95% CI 4.6
to 8.0). Ma¯ori women were intermediary (5.8 per 100 000 Ma¯ori
women,95%CI4.7to6.9)and‘‘Other’’womenwere less(4.8deaths
per 100 000 non-Ma¯ori non-Pacific women, 95% CI 4.5 to 5.0).
The relationship between deprivation and grade/stage of
tumour is shown in table 4. Women in the most deprived quintile
were more likely to have missing data (‘‘not determined’’ grade)
compared to those in the least deprived quintile. These differences
persisted after adjusting for ethnicity (OR 1.41, 95% CI 1.04 to
1.92). It is noticeable that this effect is evident only in the most
deprived quintile, and that it is not a linear effect across all levels
of deprivation. Having excluded the 2515 women with missing
data, there was no significant association between deprivation
and tumour grade. Given the high proportion of women who
were excluded, the high chance of selection bias is discussed
below. There was a suggestion that women who lived in the most
deprived areas were less likely to have regional or distant spread
compared to those in less deprived areas, but none of the stratum-
specific ORs were statistically significant. These results were not
altered following adjustment for ethnicity.
The relationship between ethnicity and grade/stage of
tumour is shown in table 5. Ma¯ori and Pacific women are more
likely to have tumours with a grade that was ‘‘not determined’’
compared to non-Ma¯ori non-Pacific women. However, this
association was not significant at the conventional level of
p,0.05. Part of this relationship was explained by deprivation.
Among women with complete data, Ma¯ori women were more
likely to have ‘‘well–differentiated’’ tumours compared to
women of ‘‘Other’’ ethnicities. Part of this effect was due to
age and deprivation, but the association remained in the
adjusted results. Again, the large number of missing data
requires these results to be interpreted with caution. There was
no difference in grade between Pacific and non-Ma¯ori non-
Pacific women. There was weak evidence to suggest that Ma¯ori
women were more likely to have ovarian cancer classified as
‘‘local’’, compared to non-Ma¯ori non-Pacific women. Part of this
effect was explained by deprivation. There was no relationship
between stage at diagnosis and ethnicity for Pacific tumour and
non-Ma¯ori non-Pacific women.
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DISCUSSION
This research has yielded key findings on the characteristics of
ovarian cancer in New Zealand women. Most notably, the
average age at diagnosis is lower in Pacific and Ma¯ori women
and they have higher age-standardised incidence of ovarian
cancer, and mortality rates, compared to non-Ma¯ori non-Pacific
women. Ma¯ori women were more likely to have ‘‘well–
differentiated’’ grade tumours, and localised staged ovarian
cancer. A significant association was found between those
women living in the most deprived quintile and having
‘‘undetermined’’ tumour grade.
The current study supports previous research that has also
shown high ovarian cancer rates in Pacific and Ma¯ori
women.7 14 15 The present findings for Pacific women are similar
to reported age-standardised rates of ovarian cancer from Pacific
Island countries including Tonga and Native Hawaiians, with
the exception of Niue, Samoa and French Polynesia, where the
incidence rates were considerably lower.6 7 16–18 More than likely,
Table 1 Distributions of ovarian cancer characteristics, by ethnicity
Non-Ma¯ori non-Pacific (n = 2746) Ma¯ori (n = 248) Pacific (n = 116) All women (n = 3110)
n (%) n (%) n (%) n (%)
Age (years)
14–19 27 (1.0) 5 (2.0) 3 (2.6) 35 (1.1)
20–24 24 (0.9) 8 (3.2) 3 (2.6) 35 (1.1)
25–29 53 (1.9) 14 (5.6) 3 (2.6) 70 (2.2)
30–34 61 (2.2) 16 (6.5) 8 (6.9) 85 (2.7)
35–39 99 (3.6) 23 (9.3) 5 (4.3) 127 (4.1)
40–44 142 (5.2) 24 (9.7) 15 (12.9) 181 (5.8)
45–49 207 (7.5) 26 (10.5) 16 (13.8) 249 (8.0)
50–54 283 (10.3) 33 (13.3) 6 (5.2) 322 (10.3)
55–59 287 (10.4) 34 (13.7) 13 (11.2) 334 (10.7)
60–64 284 (10.3) 29 (11.7) 18 (15.5) 331 (10.6)
65–69 295 (10.7) 16 (6.4) 11 (9.5) 322 (10.3)
70–74 308 (11.2) 10 (4.0) 7 (6.0) 325 (10.4)
75–79 288 (10.5) 4 (1.6) 5 (4.3) 297 (9.5)
80–84 220 (8.0) 4 (1.6) 3 (2.6) 227 (7.3)
85+ 168 (6.1) 2 (0.8) – 170 (5.5)
p,0.0001
NZDep
1–2 446 (17.3) 7 (2.9) 6 (5.8) 459 (15.7)
3–4 484 (18.8) 30 (12.4) 10 (9.6) 524 (17.9)
5–6 549 (21.4) 32 (13.3) 18 (17.3) 599 (20.6)
7–8 609 (23.7) 52 (21.6) 17 (16.3) 678 (23.3)
9–10 482 (18.7) 120 (49.8) 53 (50.9) 655 (22.5)
Missing 176 7 12 195
p,0.0001
Stage
Local 739 (26.9) 97 (39.1) 37 (31.9) 873 (28.1)
Regional 240 (8.7) 11 (4.4) 11 (9.5) 262 (8.4)
Distant 1504 (54.8) 114 (45.9) 57 (49.1) 1675 (53.8)
Unknown 263 (9.6) 26 (10.5) 11 (9.5) 300 (9.6)
p,0.0001
Grade
Undifferentiated 15 (0.5) 1 (0.4) – 16 (0.5)
Well-differentiated 112 (4.1) 15 (6.0) 6 (5.2) 133 (4.3)
Moderately differentiated 155 (5.6) 9 (3.6) 5 (4.3) 169 (5.4)
Poorly differentiated 287 (10.4) 19 (7.7) 12 (10.3) 318 (10.2)
Undetermined 2177 (79.3) 204 (82.3) 93 (80.2) 2474 (79.5)
p,0.539
a Distributions of ovarian cancer subtypes, by ethnicity
non-Ma¯ori
non-Pacific(n = 2476) Ma¯ori (n = 199) Pacific (n = 105) All women (n = 2780)
n (%) n (%) n (%) n (%)
Other tumours, not otherwise specified 478 (19.3) 47 (23.6) 21 (20.0) 546 (19.6)
Epithelial tumours 792 (32.0) 63 (31.7) 54 (51.4) 909 (32.7)
Serous tumours 993 (40.1) 73 (36.7) 23 (21.9) 1089 (39.2)
Mucinous tumours 112 (4.5) 6 (3.0) 3 (2.9) 121 (4.4)
Sex cord-stromal tumours 44 (1.8) 4 (2.0) – 48 (1.7)
Germ cell tumours 57 (2.3) 6 (3.0) 4 (3.8) 67 (2.4)
p = x2 test of association between ethnic groups, excluding missing and unknown data; NZDep, New Zealand Deprivation Index 2001 is a scale based on census information, where
1 represents the 10% least deprived and 10 represents the 10% most deprived areas in New Zealand.
n, number of registered cases, missing data = 330 cases
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the low incidence rates previously reported reflect an older
study population and lifestyle habits that were predominantly
Polynesian dietary habits at the time.16 17 The high ovarian
cancer rates in the present study, could in part be explained by
obesity, as it is well established that obesity is strongly
associated with cancer risk19–21 and Pacific women residing in
New Zealand are 2.5 times more likely to be obese than other
women in the general population.22 On the other hand,
increased parity is considered protective against this cancer,20
an association that is not consistent with the elevated incidence
rates seen in Pacific (and Ma¯ori) women who have high known
fertility rates.23 A possible biological plausible explanation for
the high incidence rates among Ma¯ori and Pacific women could
be related to certain reproductive risk factors. The use of
combined oral contraceptives is strongly protective against
ovarian cancer.24 25 However, there is currently no data on this
in Ma¯ori and Pacific women, thus further research is necessary.
The number of ovulatory cycles is highly dependent on parity,
oral contraceptive use and the time of breastfeeding.26 However,
there is less agreement in the literature as to whether the
protective effect is due to having the reduced number of
ovulatory cycles, or to the reduced stimulation of the ovary by
gonadotropin,27 or progestin-induced apoptosis.28 Further
research is in order to clarify the role of these reproductive
factors, which could partially explain why some women have
higher or lower incidence rates of ovarian cancer.
A possible genetic explanation for high incidence rates could
be that between 5 and 10% of ovarian carcinomas are directly
hereditary, and that the most common form occurs in women
with BRCA1 or BRAC2 mutations.29 The reasons underlying
why women of different ethnic groups are more likely to be
diagnosed with certain cancer subtypes are not known, thus
requires further research. It is possible that genetic predisposi-
tion may play a role in determining disease risk.
It was also found that Ma¯ori and Pacific women, and those
living in the most deprived areas, were more likely to have
missing data for graded tumours, compared to non-Ma¯ori non-
Pacific women. Information on tumour stage and grade is
Table 2 Age-specific incidence rates per 100 000 of ovarian cancer, by ethnicity, 1993–2004
Age group (years)
Non-Ma¯ori non-Pacific Ma¯ori Pacific All women
No. of cases Rate No. of cases Rate No. of cases Rate No. of cases Rate
14–19 27 1.6 5 1.2 3 1.8 35 1.6
20–24 24 1.8 8 2.7 3 2.3 35 1.9
25–29 53 3.7 14 5.1 3 2.4 70 3.8
30–34 61 3.8 16 5.9 8 6.6 85 4.3
35–39 99 6.1 23 9.4 5 5.0 127 6.5
40–44 142 9.3 24 11.8 15 18.5 181 10.0
45–49 207 14.9 26 16.7 16 25.6 249 15.5
50–54 283 23.7 33 27.9 6 12.5 322 23.6
55–59 287 29.5 34 37.2 13 35.5 334 30.4
60–64 284 34.3 29 40.9 18 64.2 331 35.7
65–69 295 38.8 16 31.9 11 50.4 322 38.7
70–74 308 42.7 10 30.9 7 45.2 325 42.3
75–79 288 47.6 4 21.5 5 53.1 297 46.9
80–84 220 50.3 4 41.6 3 59.5 227 50.2
85+ 168 45.4 2 49.6 – – 170 45.1
ASR* (95% CI) 9.4 (8.9 to 9.7) 10.1 (8.8 to 11.5) 11.2 (9.5 to 14.0) 9.6 (9.2 to 9.9)
The crude incidence rate for all women was 15.8 per 100 000.
*ASR, age-standardised rates, standardised to Segi’s (1960) population weights.
Table 3 Age-specific mortality rates per 100 000 of ovarian cancer, by ethnicity, 1993–2004
Age group
(years)
Non-Ma¯ori non-Pacific Ma¯ori Pacific All Women
No. of deaths MR No. of deaths MR No. of deaths MR No. of deaths MR
14–19 3 0.2 1 0.2 3 – 4 0.2
20–24 – – – – – – – –
25–29 5 0.3 1 0.4 5 – 6 0.3
30–34 16 1.0 5 1.8 16 1.7 23 1.2
35–39 10 0.6 6 2.5 10 0.9 17 0.9
40–44 35 2.3 11 5.4 35 3.7 49 2.7
45–49 54 3.9 10 6.4 54 17.6 75 4.7
50–54 119 9.9 19 16.1 119 8.4 142 10.4
55–59 158 16.2 11 12.0 158 5.4 171 15.5
60–64 174 21.0 23 32.5 174 39.2 208 22.4
65–69 201 26.5 18 35.9 201 45.8 229 27.6
70–74 229 31.8 8 24.8 229 38.7 243 31.6
75–79 229 37.9 4 21.5 229 31.8 236 37.3
80–84 219 50.0 3 31.2 219 39.7 224 49.5
85+ 164 44.4 2 49.6 164 – 166 44.1
ASR
(95% CI)
4.8 (4.5 to 5.0) 5.8 (4.7 to 6.9) 6.3 (4.6 to 8.0) 4.9 (4.7 to 5.2)
The crude mortality rate for all women was 9.1 per 100 000.
ASR, age-standardised rates, standardised to Segi’s (1960) population weights.
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important as it provides an indication of the likely prognosis
and optimal treatment options. For Pacific women, and those in
deprived areas, a likely explanation is that these women
presented with advanced disease, which is not treated surgi-
cally, and therefore histological specimens were probably
unavailable for assessment. Recent data from the New
Zealand Health Survey indicated that women aged 20–69 years
in the most deprived quintile (based on NZDep2006),22 and
Pacific women were significantly less likely to utilise cancer
prevention services available from their health care provider.30 In
the present study, as Pacific women were more likely to be
diagnosed at a later stage of ovarian cancer (regional/distant)
compared to Ma¯ori women, this in part may explain the higher
mortality rates among Pacific women. Further work is necessary
to investigate why Pacific women (and those from lower
socioeconomic backgrounds) tend to present with advanced
stage of disease, and in particular to identify reasons for lower
access rates and participation in health support services30 and, or
whether cultural factors influence their health behaviours
(Personal communication. Steve Fleming, 2008).
Ma¯ori women on the other hand, were more likely to be
diagnosed at an earlier ‘‘age’’ and ‘‘stage’’ of the disease, than
non-Ma¯ori non-Pacific women. The authors cannot explain this
finding, other than the possible notion that Ma¯ori women who
presented with early stage ovarian cancer were possibly treated
for other co-existing medical conditions, which may have led to
an earlier diagnosis (Personal communication. Steve Fleming,
2008). This finding echoes that of Robson and others who
reported that Ma¯ori women were more likely to be diagnosed
with ovarian cancer at an earlier stage of the disease than non-
Ma¯ori women,14 although they did not find any significant
differences between Ma¯ori and non-Ma¯ori when adjusted for
age. Reasons for this remain unclear; however, Ma¯ori women
being diagnosed at an earlier stage of disease may explain their
likely survival advantage over Pacific women, as previously
found by Jeffreys and co-workers.31 Additional information and
understanding of diagnostic patterns of care in Ma¯ori women
could benefit others, especially if this could be translated to
other ethnic groups.
Finally, the present study found that Pacific women present
more with epithelial ovarian subtype tumours whereas Ma¯ori
and non-Ma¯ori non-Pacific women appear more susceptible to
serous ovarian cancers. To the authors’ knowledge, no studies
have compared ovarian cancer subtypes between different
ethnic populations in the same country, or between women of
the same ethnic origin living in different countries, thus further
research to examine why specific ovarian cancer subtypes appear
more common in different ethnic groups may be useful.5 29
Table 4 Association between deprivation level and tumour features: grade and stage
OR* (95% CI) OR** (95% CI)
Grade of tumour: not determined vs poorly/moderately/well-differentiated tumours (n = 2899)
NZDep 1 1.00
NZDep 2 0.94 (0.69 to 1.26) 0.93 (0.69 to 1.25)
NZDep 3 1.18 (0.88 to 1.60) 1.17 (0.87 to 1.58)
NZDep 4 1.14 (0.86 to 1.52) 1.13 (0.84 to 1.50)
NZDep 5 1.48 (1.10 to 2.01) 1.41 (1.04 to 1.92)
Grade of tumour: well- vs poorly/moderated differentiated tumours (n = 595)
NZDep 1 1.00
NZDep 2 1.40 (0.71 to 2.78) 1.37 (0.69 to 2.73)
NZDep 3 1.56 (0.78 to 3.11) 1.54 (0.77 to 3.06)
NZDep 4 1.52 (0.79 to 2.95) 1.48 (0.76 to 2.87)
NZDep 5 1.36 (0.67 to 2.73) 1.30 (0.64 to 2.67)
Stage of tumour: regional/distant vs local stage ovarian cancer (n = 2640)
NZDep 1 1.00
NZDep 2 0.99 (0.74 to 1.35) 1.00 (0.74 to 1.35)
NZDep 3 1.04 (0.77 to 1.39) 1.04 (0.77 to 1.39)
NZDep 4 0.97 (0.73 to 1.28) 0.97 (0.73 to 1.29)
NZDep 5 0.84 (0.64 to 1.12) 0.85 (0.64 to 1.14)
*Adjusted for age.
**Adjusted for age and ethnicity.
Table 5 Association between ethnicity and tumour features: grade and stage
OR* (95% CI) OR** (95% CI)
Grade of tumour: not determined vs poorly/moderately/well-differentiated tumour s (n = 3,094)
Non-Ma¯ori non-Pacific 1.00
Ma¯ori 1.36 (0.96 to 1.92) 1.24 (0.87 to 1.78)
Pacific 1.13 (0.71 to 1.81) 1.24 (0.73 to 2.10)
Grade of tumour: well- vs moderately/poorly differentiated tumour s (n = 620)
Non-Ma¯ori non-Pacific 1.00
Ma¯ori 1.53 (0.77 to 3.03) 1.42 (0.71 to 2.85)
Pacific 0.99 (0.37 to 2.65) 0.82 (0.25 to 2.67)
Stage of tumour: regional/distant vs local stage ovarian cancer (n = 2810)
Non-Ma¯ori non-Pacific 1.00
Ma¯ori 0.86 (0.64 to 1.16) 0.92 (0.67 to 1.25)
Pacific 1.12 (0.73 to 1.73) 1.13 (0.71 to 1.78)
*Adjusted for age.
**Adjusted for age and deprivation.
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Limitations
There are a number of limitations to the study that should be
considered. First, the precision with which the authors were
able to determine ethnic-specific ovarian cancer rates was
limited by the small numbers of Ma¯ori and Pacific cases.
Second, there is diversity between specific Pacific ethnic groups;
thus, the present findings are not directly comparable to studies
of women in the Pacific Islands.6 7 16–18 Third, although the
NZCR endeavours to differentiate between New Zealand
resident and non-resident cases, there is still the potential that
some non-resident cases have been included in the present
analyses, resulting in inflated incidence rates. Furthermore,
some cancer registrations with unspecified ethnicity were
included in the non-Ma¯ori non-Pacific group, which would
have reduced the observed differences between ethnic groups.2
The final limitation relates to the large proportion of women in
the present sample with missing data. The reasons underlying
this could be attributed to errors in coding, or that histopathol-
ogy samples were not taken, or that the different information
sources (clinical, radiological, histological, autopsy or death
certificate) providing cancer diagnosis were incomplete. The
lack of complete information on stage and grade at diagnosis
will affect the precision of the estimates produced by this study
introducing the possibility of selection bias.
Conclusion
In conclusion, this study found that Pacific and Ma¯ori women
experience higher incidence and mortality from ovarian cancer
compared to non-Ma¯ori non-Pacific women, although Ma¯ori
women were more likely to have better prognostic factors (local
stage and well-differentiated tumours), than non-Ma¯ori non-
Pacific women. It was found that ovarian cancer subtypes
differed by ethnic group and further research examining this
area is warranted. At the same time, more work is needed to
improve current cancer prevention strategies, particularly in
Pacific women.
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What is already known on this subject
c In New Zealand, ovarian cancer has the eighth highest number
of female cancer registrations, and the fifth highest number of
female cancer deaths.
c Few studies have examined ovarian cancer incidence and
mortality between ethnic groups in the same country, or
between women of the same ethnic origin living in different
countries.
c This study describes the incidence and mortality rates of
women with ovarian cancer between three ethnic groups in
New Zealand.
What this study adds
c It has been shown that in New Zealand, Ma¯ori women have
better prognostic factors than non-Ma¯ori non-Pacific women
from ovarian cancer; however, the reasons remain unclear,
and further research is needed is understand this relationship.
c This study also highlights the necessity of improving cancer
prevention strategies particularly for women who are of Pacific
ethnicity.
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